Congress funds women's health research push, seats pharma at the table
H.R. 7694 — Gwenn’s Law · Filed by Josh Gottheimer (D-NJ) · 3 cosponsors · Introduced Feb 25, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to run two public awareness campaigns—one to increase women's participation in NIH clinical trials generally, and another focused on bleeding and clotting disorders—and establishes a permanent interagency task force to coordinate federal efforts on rare disease research and treatment, with particular attention to conditions affecting women. The bill authorizes $10 million per year for five years for each campaign and requires HHS to produce an action plan within 180 days on coordinating rare-disease research that disproportionately affects women.
Why we flagged it
The bill's core function is establishing federal coordination mechanisms and public awareness campaigns for women's health and rare disease research—a public health infrastructure measure, not a commemorative or vanity bill despite its eponymous title.
What the text implies
- The task force includes four appointed positions for 'biopharmaceutical innovators' with respect to rare diseases, creating a formal channel for private pharmaceutical industry input into federal research prioritization and incentive design—potentially shaping which rare diseases receive public research support.
- The bill's focus on 'rare diseases and conditions that disproportionately impact women' may create a research-funding bias toward conditions affecting women, potentially reducing relative attention to rare diseases affecting other populations, though this reflects a deliberate policy choice rather than a hidden mechanism.
The full analysis lists 3 implications of this text.
Who stands to gain
biopharmaceutical companies developing rare disease treatments; clinical research institutions and hospitals conducting NIH-funded trials; private health plan administrators (task force members)